Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model
暂无分享,去创建一个
Andrea Pavesi | Antonio Bertoletti | Giulia Adriani | R. Kamm | A. Bertoletti | S. Wong | S. Lee | A. Pavesi | Sharon Wei Ling Lee | Erica Ceccarello | Anthony Tanoto Tan | Roger Dale Kamm | Siew Cheng Wong | A. Tan | E. Ceccarello | Giulia Adriani | Erica Ceccarello
[1] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[2] Roger D. Kamm,et al. A 3D neurovascular microfluidic model consisting of neurons, astrocytes and cerebral endothelial cells as a blood-brain barrier. , 2017, Lab on a chip.
[3] D. Campana,et al. A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus , 2013, Molecular therapy. Nucleic acids.
[4] Andrea Pavesi,et al. A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors. , 2017, JCI insight.
[5] V. Gelfanov,et al. IL-15 Promotes Survival But Not Effector Function Differentiation of CD8+ TCRαβ+ Intestinal Intraepithelial Lymphocytes , 1999, The Journal of Immunology.
[6] A. Bertoletti,et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. , 2015, Journal of hepatology.
[7] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[8] A. Fauci,et al. The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands , 2008, The Journal of Immunology.
[9] A. Doseff,et al. Monocyte Subsets and Their Role in Tumor Progression , 2012 .
[10] A. Pavesi,et al. Using microfluidics to investigate tumor cell extravasation and T-cell immunotherapies , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[11] Andrea Pavesi,et al. Advances in microfluidics in combating infectious diseases , 2016, Biotechnology Advances.
[12] T. Tsai,et al. Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. , 2016, World journal of gastroenterology.
[13] B. Ksander,et al. Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80 , 2011, The Journal of Immunology.
[14] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[15] Roger D. Kamm,et al. Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening , 2013, Advanced healthcare materials.
[16] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[17] Roger D Kamm,et al. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[18] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[19] K. Odunsi,et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer , 2016, Oncoimmunology.
[20] Andrea Pavesi,et al. Microfluidic models for adoptive cell-mediated cancer immunotherapies. , 2016, Drug discovery today.
[21] Roger D. Kamm,et al. Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and β2 integrin interactions , 2015, Oncotarget.
[22] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[23] M. J. You,et al. The Role of Tumor-Associated Macrophages in Leukemia , 2019, Acta Haematologica.
[24] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[25] A. Elia,et al. T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors. , 2017, Cancer research.
[26] P. Frosch,et al. Effects of nIFN beta and rIFN gamma on growth and morphology of two human melanoma cell lines: comparison between two- and three-dimensional culture. , 1994, International Journal of Cancer.
[27] V. Gelfanov,et al. IL-15 promotes survival but not effector function differentiation of CD8+ TCRalphabeta+ intestinal intraepithelial lymphocytes. , 1999, Journal of immunology.
[28] M. Grompe,et al. Extensive double humanization of both liver and hematopoiesis in FRGN mice , 2014, Stem cell research.
[29] V. Boussiotis,et al. Biochemical Signaling of PD-1 on T Cells and Its Functional Implications , 2014, Cancer journal.
[30] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[31] R. Kamm,et al. Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels , 2012, Nature Protocols.
[32] R. Davis,et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[33] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] T. Cloughesy,et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma , 2017, Neuro-oncology.
[35] Roger D. Kamm,et al. M2a macrophages induce contact-dependent dispersion of carcinoma cell aggregates , 2016 .
[36] James P. Freyer,et al. The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model , 2004, Journal of biomolecular screening.
[37] Jiasen Cheng,et al. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. , 2007, Blood.
[38] J. Gulley,et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. , 2014, Translational lung cancer research.
[39] Roger Williams,et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. , 2015, Gastroenterology.
[40] A. Bertoletti,et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.
[41] F. Ginhoux,et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma , 2016, Oncoimmunology.
[42] Ton N. Schumacher,et al. Adoptive cellular therapy: A race to the finish line , 2015, Science Translational Medicine.
[43] G. Freeman,et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status , 2007, AIDS.
[44] H. Acker,et al. Effects of nIFN β and rifn γ on growth and morphology of two human melanoma cell lines: Comparison between two‐and three‐dimensional culture , 1994 .
[45] F. Q. Ribeiro. The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.
[46] J. Larrubia,et al. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. , 2016, World journal of gastroenterology.
[47] R. Kamm,et al. Microfluidics: A new tool for modeling cancer-immune interactions. , 2016, Trends in cancer.
[48] S. Qiu,et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.
[49] F. Hodi,et al. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 , 2012, Clinical Cancer Research.
[50] Tobias Schmelzle,et al. Engineering tumors with 3D scaffolds , 2007, Nature Methods.
[51] D. Tamang,et al. Low dose IL-15 induces snap arming of CD44(low) T lymphocytes in the absence of antigen. , 2008, Cellular immunology.
[52] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[53] P. Tien,et al. PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients , 2011, International journal of cancer.
[54] Alison P McGuigan,et al. The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery? , 2018, Advanced healthcare materials.
[55] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] J. Pollard,et al. Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.
[57] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[58] R. Krance,et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.
[59] W. Liang,et al. Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer , 2015, Medicine.
[60] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[61] Roger D. Kamm,et al. Modeling the Blood-Brain Barrier in a 3D triple co-culture microfluidic system , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[62] M. Bruno,et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. , 2017, Gastroenterology.
[63] F. Ginhoux,et al. Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. , 2017, Journal of hepatology.
[64] M. Nishimura,et al. Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. , 2016, Cancer research.
[65] Jing Xu,et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.
[66] H. Shiku,et al. Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. , 2013, Blood.
[67] Zhi Chen,et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. , 2008, Molecular immunology.
[68] M. Poupon,et al. Distinctive alterations of invasiveness, drug resistance and cell–cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant , 2004, Clinical & Experimental Metastasis.
[69] S. Gordon,et al. Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.
[70] N. Restifo,et al. Cellular constituents of immune escape within the tumor microenvironment. , 2012, Cancer research.
[71] J. Pollard,et al. Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.
[72] J. Mcclendon. “Race” to the Finish Line , 2017 .
[73] R. Kamm,et al. A Facile Method to Probe the Vascular Permeability of Nanoparticles in Nanomedicine Applications , 2017, Scientific Reports.
[74] P. Allavena,et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.
[75] Roger D. Kamm,et al. Engineering a 3D microfluidic culture platform for tumor-treating field application , 2016, Scientific Reports.
[76] N. Mitsiades,et al. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.